Drug Development

NDA submitted to U.S. FDA for advanced prostate cancer drug

Published in Cancer Weekly, February 8th, 2005

Abbott (ABT) announced that it has submitted a New Drug Application (NDA) for its oral agent Xinlay (atrasentan) to the U.S. Food and Drug Administration (FDA) seeking approval of Xinlay for the treatment of metastatic hormone-refractory prostate cancer, an advanced stage of the disease that no longer responds to hormone treatment and has spread to other parts of the body, such as the bone.

"The submission of this New Drug Application is an important milestone in Abbott's commitment to prostate cancer patients and their families," said John Leonard, MD, vice president, Global Pharmaceutical Development at Abbott. "Our novel pipeline for drug development has the...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Cancer Weekly

Source: Cancer Weekly (2005-02-08)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry